

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF FIRST DOSING OF FIRST PATIENT
OF B7H4X4-1BB BISPECIFIC ANTIBODY (HBM7008) PHASE I TRIALS

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 has been completed. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors.

HBM7008 is generated from our innovative immune-cell-engager HBICE® platform, leveraging the advantages of fully-human transgenic mice and HCAb platforms. It targets Tumor Associated Antigen (B7H4) and mediates crosslinking T cell activation through 4-1BB. B7H4 is overexpressed on a variety of solid malignancies, including breast, NSCLC, ovarian, and endometrial tumor. With its crosslinking dependent specificity on tumors and potent immune modulation activity, HBM7008 has shown excellent safety profile with strong anti-tumor efficacy in the pre-clinical study, including completed response observed in mouse tumor model.

As the first-in-class bispecific antibody targeting B7H4 and 4-1BB, HBM7008 is expected to lead the development of next-generation immunotherapeutics. Following its global innovation and development strategy, the Company will advance the global clinical development project of HBM7008 at full speed.

About HBM7008

HBM7008 is a bispecific antibody targeting Tumor Associated Antigen B7H4x4-1BB that not only displays high potency in T cell co-stimulation and tumor growth inhibition, but may also translate to better safety due to its strict dependency on the presence of tumor antigen to mediate crosslinking T cell activation. It is the first-in-class bispecific antibody targeting B7H4x4-1BB. HBM7008 is a fully human bispecific antibody developed from the HBICE® platform of the Company. Its unique specificity on tumors and immune modulation activity makes it a promising therapeutics in PD-L1 negative or PD-1/PD-L1 resistant patients. It also has the potential to avoid the 4-1BB liver toxicity risk observed in other products its innovative biology mechanisms and bispecific design.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM7008. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 25 May 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.